Programme

To download a printable version of the programme please click here.

Friday 13 October

9.00am - 5.15pm  Breast Cancer Summit
2.00pm - 4.00pm  Exhibitor pack in
2.00pm - 5.00pm  Registration desk open

 

Saturday 14 October

7.30am - 5.30pm  Registration desk open 
Satellite Event

MSD Breakfast Symposium

8.00am 

Management of brain metastases in the era of immune checkpoint blockade

Case presentations and panel discussion

Invited speaker: Victoria Atkinson, Queensland
Moderator: Rosalie Stephens, Auckland City Hospital
Christopher Jackson, Southern District Health Board
Peter Heppner, Auckland
Silvia Chiara Formenti, Weill Cornell Medicine, 
New York            

Breakfast served from 7.30am
9.30am Conference opening 
9.30am Powhiri
9.35am President's welcome
Ben Lawrence, Auckland

Session 1:

The tumour microenvironment in cancer progression and therapy

Chairs: Andrew Macann and Francis Hunter

Presented in partnership with the Maurice Wilkins Centre for Molecular Biodiscovery

9.40am New aspects of tumour hypoxia biology
Invited speaker: Adrian Harris, University of Oxford 
10.10am  Infiltrating immune cells that predict patient outcome
Invited speaker: Roslyn Kemp, University of Otago
10.40am Elevation of the p53 isoform, delta133p53ß, in glioblastoma with an immune suppressive signature and poorer prognosis
Tania Slatter, University of Otago
10.55am Distinct microbiome patterns associate with colorectal cancer molecular subtypes
Rachel Purcell, University of Otago
11.10am Morning tea 

Session 2:

 


Early-phase clinical trials

Presented in partnership with the European Society for Medical Oncology
Chairs: Michael Jameson and Anne O'Donnell

11.40am  Accelerated clinical evaluation of drug combinations based on biological insights
Invited speaker: Josep Tabernero, Vall d'Hebron University Hospital, Barcelona
12.10pm Combination phase 1 oncology trials
Invited speaker: Mark McKeage, University of Auckland
12.25pm Trials and tribulations
Invited speaker: Sanjeev Deva, Auckland District Health Board Medical Oncology
12.40pm An open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid
Paula Barlow, Auckland District Health Board
12.55pm Lunch 

Session 3: 


PHARMAC Young Researcher Awards

Chairs: Richard Isaacs and Melanie McConnell

1.40pm Effects of Exercise on the Breast Tumour Microenvironment in Hyperlipidaemic Mice
Linda Buss, University of Otago
  Investigating strategies to improve access to clinical trial opportunities in oncology in New Zealand – INSIGHT study
Yeojeong So, Auckland District Health Board
  Cancer-associated adipocytes alter proteomic expression of human breast cancer cells
Rebekah Crake, University of Otago
  30 Day Mortality after Systemic Anticancer Treatment as a Real World Quality of Care Indicator: The Northland Experience 
Edmond Ang, Northland District Health Board
  Informing Immunotherapy: Studying Innate-Like T Cells in Cancer
Ellie-May Jarvis, Malaghan Institute of Medical Research
  Southern Blood and Cancer Service FEC-D Chemotherapy for Early Breast Cancer, an audit of Febrile Neutropenia, Toxicity and Treatment Interruption
Tessa Morris, Southern District Health Board
  Is there a role for ascorbate in regulating hypoxia factors in renal cell carcinoma?
Christina Wolhrab, University of Otago
  Impact of Formalised Multidisciplinary Meeting on Referral Rate for Neoadjuvant Chemotherapy and Survival for Muscle Invasive Bladder Cancer: Auckland Experience
Michael Lee, Auckland District Health Board
  The role of BCL6 in glioblastoma
Nicole Jones, Victoria University
  Predicting the risk of mortality and recurrence in breast cancer patients:A systematic review of risk prediction models
Tung Phung, University of Auckland

Session 4: 


Clinical and scientific poster discussions

Discussant: Michael Findlay, Auckland
Discussant: Anita Dunbier, Otago
3.10pm The Women's Wellness after Cancer Program (WWACP): A multicentre randomised controlled trial of an e-enabled health promotion intervention?
Alexandra McCarthy, University of Auckland

A retrospective audit of compliance with BRCA testing guidelines in the Medical Oncology clinic in Auckland City Hospital
Edbert Wong, Auckland District Health Board
3.40pm  The NETwork! Registry: Preliminary data suggests increasing incidence in a national study of neuroendocrine cancer in New Zealand (NZ)
Kate Parker, University of Auckland

Nanopore sequencing of full-length BRCA1 mRNA transcripts reveals co-occurrence of known exon skipping events
Logan Walker, University of Otago
4.10pm Afternoon tea 

Session 5: 



Tissue banking, molecular pathology and diagnostics

Chairs: Peter Browett and Annette Lasham

4.40pm Molecular pathology of rare types of breast cancer: More than tumour philately
Invited speaker: Jorge Reis-Filho, Memorial Sloan Kettering Cancer Center, New York
5.10pm Tissue Banking in New Zealand: What does the future hold?
Peter Browett, University of Auckland
Bridget Robinson, University of Otago
Cristin Print, University of Auckland
Cherie Blenkiron, University of Auckland

5.30pm Open discussion of priorities in local tissue banking
Award: Roche Translational Cancer Research Fellowship
5.50pm Immunology in Clinical Research: Maximising patient data
2016 Recipient: Roslyn Kemp, University of Otago
5.55pm Announcement of the 2017 Roche Translational Cancer Research Fellowship
6.00pm Bruce Cain Memorial Lecture
Dissecting colorectal cancer in multiple targetable subtypes

Bruce Cain Memorial Lecturer: Josep Tabernero, Barcelona, Spain
7.00pm Conference dinner at the Auckland Art Gallery



Sunday 15 October

7.30am - 4.30pm  Registration desk open
Satellite Event Roche Foundation Medicine Breakfast Symposium
8.00am 
Genomics in clinical oncology - Hype or reality?
Case presentations and panel discussion

Moderator: Ben Lawrence, University of Auckland
Sharon Pattison, University of Otago
Cristin Print, University of Auckland
Michelle Wilson, University of Auckland
James Creeden, Medical Director, Roche Foundation Medicine Asia Pacific

Breakfast served from 7.30am


9.10am Incoming President's welcome
Roslyn Kemp, University of Otago

Session 6: 



Translational radiation oncology

Chairs: Giuseppe Sasso and Bill Wilson

9.15am Optimal radiation and immune checkpoint blockade combinations
Invited speaker: Silvia Chiara Formenti, Weill Cornell Medicine, New York
9.45am  HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC: Radiation effects on the immune rheostat in HNSCC that influence immune activation vs immune suppression in tumours, and homeostatic balance vs chronic inflammation / fibrosis in normal tissues.
Invited speaker: Andrew Macann, Auckland District Health Board Radiation Oncology
10.05am Efficacy and Sensitivity Determinants of Evofosfamide in Head and Neck Squamous Cell Carcinoma
Francis Hunter, University of Auckland
10.20am Proteomic profiling of predictive biomarkers for hypoxia-activated prodrugs in head and neck squamous cell carcinomas
Yongchuan Gu, University of Auckland
10.35am Morning tea

Session 7:



Genomics, predisposition and precision oncology

Chairs: Sharon Pattison and Andrew Shelling

11.00am Drowning in our success: post-GWAS studies of breast cancer risk
Invited speaker: Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute
11.30am Genomics for precision oncology: How hard can it be?
Invited speaker: Cristin Print, University of Auckland
11.50am Genomics in Haematological Malignancies: The future of genomics in solid tumors?
Invited speaker: Stefan Bohlander, University of Auckland
12.10pm Population genetic testing for breast cancer susceptibility
Ian Campbell, Peter MacCallum Cancer Centre
12.25pm Identification of Cooperating Genetic Lesions in Defined Signaling Pathways in CALM-AF10 Driven Murine Leukaemia Models
Rhea Desai, University of Auckland
12.40pm Lunch
'Meet and speak' with patient representative groups
Satellite Event: Professional Development Lunch Session
 12.40pm Career opportunities after a PhD in cancer research
Andrew Shelling, Professor, Auckland University
Andrew Kelly, Executive Director, BioPacific Partners
Stuart Ryan, Medical Manager, Roche NZ
Andy Shenk, CEO, Auckland UniServices Ltd
Paul O'Sullivan - Medical-Science Liaison, MSD
Award: NZSO Translational Research Award
1.25pm Presentation of the NZSO Translational Research Award
1.30pm NZSO Translational Research Award Lecture: To PI-3-Kinase and back again
Peter Shepherd, University of Auckland

Session 8: 



Drug discovery and novel approaches to therapy

Chairs: Mark McKeage and Bill Denny

2.00pm Discovery of hypoxia-selective kinase inhibitors
Invited speaker: Jeff Smaill, University of Auckland
2.20pm Converting toxic duocarmycin natural products to tumour-selective anticancer agents
Invited speaker: Moana Tercel, University of Auckland
2.40pm Next-generation hypoxic cell radiosensitisers: Nitroimidazole alkylsulfonamides
Michael Hay, University of Auckland
2.55pm  Mitochondrial transfer in gliblastoma: breaking bioenergetic boundaries
Mike Berridge, Malaghan Institute of Medical Research
3.10pm Closing remarks from the convener
Francis Hunter, University of Auckland 
3.15pm Afternoon tea
3.35pm NZSO Annual General Meeting 

Monday 16 October

10.00am - 3.30pm Cancer Trials NZ Annual Scientific Meeting

Click here to download the programme or visit the website here.

Contact Sarah Benge to register s.benge@auckland.ac.nz

 

Contacts

Ben LawrenceNZSO President

Roslyn KempVice President

Ken Dempster NZSO Membership

Charlotte Sloane Conference and Website